Filing Flows › Pharma-Bio Serv (PBSV) › Q2 FY26
Pharma-Bio Serv (PBSV) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed Jun 15, 2026
Pharma-Bio Serv (PBSV) reported revenue of $2.7M for the second quarter fiscal 2026 (Q2 FY26), +12% from a year earlier and +18% from the quarter before. Operating margin was 5.4%, net earnings $233K (8.6% of revenue).
Pharma-Bio Serv, Q2 FY26: revenue $2.7M (+12% year over year), operating margin 5.4%, net earnings $233K, operating cash flow −$365K. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.7M | +18% | +12% |
| Gross profit | $902K | +25% | +10% |
| Operating profit | $145K | — | — |
| Net earnings | $233K | +609% | +144% |
| Operating cash flow | −$365K | — | — |
What changed
Revenue was $2.7M in Q2 FY26, up 12% year over year and up 18% from the previous quarter.
Gross margin was 33.4%, down 0.5 points from Q2 FY25. Operating profit was $145K, a 5.4% margin (up 9.4 points year over year). Operating expenses fell 17% while revenue rose 12%. Net earnings were $233K, up 144% year over year. The effective tax rate was 2.7%. Non-operating items added $95K, 40% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$365K. Non-cash charges added back $14K of depreciation and amortization and $9K of share-based compensation. Working capital and other items used $621K. Capital expenditures of $2K exceeded it, leaving free cash flow of −$368K.
Questions
What was Pharma-Bio Serv's revenue in the second quarter fiscal 2026?
Pharma-Bio Serv (PBSV) reported revenue of $2.7M for the second quarter fiscal 2026 (Q2 FY26), +12% from a year earlier and +18% from the quarter before.
Was Pharma-Bio Serv profitable in the second quarter fiscal 2026?
Operating profit was $145K (5.4% of revenue) and net earnings $233K.
Source: Pharma-Bio Serv 10-Q on SEC EDGAR.